Grezac

This research aims to evaluate the performance of the AccuPowerae HBV Quant Kit Bioneer ExiStationtrade FA 96384 diagnostic kit for hepatitis B virus HBV in France. Hepatitis B is a liver infection caused by the HBV virus, which can lead to chronic liver disease in some individuals. The study is conducted as part of the CE marking process to meet European regulatory standards IVDR RE 2017746. The trial involves patients with hepatitis B who have a positive viral load, focusing on how well the kit measures HBV DNA in blood samples. The study involves collecting blood samples prospectively from patients with hepatitis B at three Cerba Healthcare group laboratories in France. The AccuPower kit will be tested on both serum and plasma samples from these patients. The study does not involve treatment but focuses on diagnostic performance comparison. The main goal is to assess the consistency and reliability of viral load results between serum and plasma using this PCR-based diagnostic tool. Participants will provide blood samples as part of their routine care, and their viral loads will be measured using the AccuPower kit. Researchers will compare the viral load results from serum and plasma over a four-month period to evaluate the kits performance. There are no additional treatments or interventions. Participant safety and informed consent are ensured, and the study is observational. Total participation time depends on sample collection and routine monitoring.

Researchers are conducting a pilot phase of a longitudinal observational cohort study involving family clusters that include a patient with Alzheimers disease, an informal caregiver, and at least one first-degree relative. The study aims to explore risk and prognostic factors such as blood-based biomarkers in first-degree relatives and patients, as well as to understand caregiver health, challenges, and needs. This initial study will assess the feasibility of a larger-scale research effort. The study will follow 150 family clusters over two years, with visits at expert memory centers and online questionnaires. Patients with mild to moderate Alzheimers disease, their caregivers, and first-degree relatives will participate. The study will collect data at baseline, 12 months, and 24 months, including medical examinations and regular health questionnaires completed in person or online. Participants will undergo medical evaluations and provide information through questionnaires about their health and caregiving experiences. Researchers will monitor recruitment and retention rates over 18 to 24 months and assess cognitive function over 60 months. The study will also track caregiver health and needs to gain a better understanding of the diseases impact on families.

Liver transplantation involves complex changes in blood flow during different surgical stages, which can make monitoring heart function challenging. Researchers are comparing two common monitoring methods transpulmonary thermodilution and transesophageal echocardiography, to see how they track changes in cardiac index during liver transplant surgery. This observational study evaluates these methods to understand their reliability throughout the procedure. Participants undergoing liver transplantation are monitored using both thermodilution and transesophageal echocardiography at four key surgery stages after anesthesia begins, during the anhepatic phase, at reperfusion, and during the surgical anastomosis of the biliary ducts. Measurements include cardiac index values before and after an end-expiratory occlusion test, along with echocardiographic visualization of the surgical anastomosis to assess blood flow and vessel diameter. During the study, patients have their heart function and blood flow monitored closely at these specific time points. Researchers collect demographic, biological, and post-operation data to analyze alongside cardiac measurements. The main outcome is comparing cardiac index changes measured by the two methods at these surgical stages to assess their consistency and reliability in the liver transplant setting.

Dalbavancin DAL is an antibiotic that belongs to the lipoglycopeptide family, designed to fight certain Gram-positive bacterial infections. It has a long half-life and can penetrate tissues like skin, bones, joints, lungs, and the peritoneal space. This research evaluates the effectiveness and safety of DAL when used as suppressive therapy to manage acute or chronic infections that have not been successfully treated with previous antibiotics or surgeries. The study looks at adults aged 18 and older who received DAL as suppressive antibiotic therapy between July 2019 and December 2024. This observational study gathers information about patient demographics, medical history, and antibiotic treatment to assess how well DAL controls long-standing infections. Participants who received DAL for other purposes or who were under 18 years old are not included. During the study, researchers will monitor the stability of infections over one year, using the date of the last visit for patients lost to follow-up or followed less than a year. Data collected include infection status, patient characteristics, and treatment details. The study aims to understand DALs ability to maintain infection control and its safety in this patient group, supported by ongoing medical management and follow-up observations.

Researchers are evaluating the effectiveness of a 30 microgram sublingual sufentanil tablet for managing moderate to severe pain in adults with isolated trauma to an upper or lower limb. This Phase 3 study compares this treatment to the usual pain management protocol used in the emergency department at Clermont-Ferrand. Pain is a common reason for emergency visits, but current opioid treatments have limitations such as long wait times and resource demands, so this study aims to assess if the sublingual tablet offers advantages in acute pain control. Participants are randomly assigned to one of two groups one receiving the standard pain treatment used in the emergency department and the other receiving a single 30 mcg sublingual sufentanil tablet. The study focuses on adults experiencing moderate to severe monotraumatic pain and measures pain levels using a numerical rating scale. The sublingual tablet offers a non-invasive option that may have a faster onset and easier dosing compared to intravenous opioids. During the study, pain scores will be recorded at the start and 60 minutes later to evaluate effectiveness. Additional assessments include monitoring potential side effects, blood pressure, heart rate, oxygen saturation, and breathing rate at multiple time points up to three hours after treatment. Patient satisfaction with pain management will also be measured. The trial starts in April 2025 and will continue until April 2027, ensuring thorough evaluation and safety monitoring.

Researchers are investigating acute brain injuries such as subarachnoidal hemorrhage, intracranial hypertension, and acute trauma brain injury. The study aims to understand brain pathophysiology during the first week after injury by exploring brain oxygen use, metabolic disorders, and electrical activity through various monitoring techniques. The goal is to identify valuable biomarkers using multimodal monitoring to better track brain function and prevent delayed injuries. The study involves observing patients admitted to neurocritical care who are monitored with the CNS MOBERGae system. Researchers will study the correlation between different cerebral autoregulation indexes like PRx, ORx, and Cox, and also analyze EEG patterns to detect early prognostic changes. Monitoring occurs from 1 to 15 days after the acute brain injury. Participants will be closely observed in the neurocritical care unit with continuous multimodal monitoring. The main outcome measured is the correlation between ORx and PRx autoregulation indexes. No experimental treatments are given as this is an observational study. Data collection includes neurological exams and monitoring brain activity and oxygen levels. The study duration covers the first week post injury with ongoing monitoring up to 15 days.